エーザイ、DIAN-TUは優性遺伝アルツハイマー病に対するタウ標的療法を評価する次世代臨床試験において、その基礎療法となる抗アミロイド療法としてレカネマブを選定 Nov 09, 2021 14:00 JST Read More
Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer's Disease Nov 09, 2021 09:46 HKT/SGT Read More
EC Healthcare Acquires Specialty Medical Services Centers in Hong Kong Nov 08, 2021 08:10 HKT/SGT Read More
エーザイ、第14回アルツハイマー病臨床試験会議(CTAD)において早期AD治療薬候補レカネマブの臨床第IIb相における臨床、バイオマーカー、安全性に関する結果を含むADパイプラインの最新データを発表 Nov 04, 2021 13:00 JST Read More
エーザイ、デジタルガレージと共同で認知症に関わるスタートアップとの協業育成プログラム「Onlab Bio Dementia(Open Network Lab BioHealth Dementia Innovation Challenge)」を始動 Nov 04, 2021 13:00 JST Read More
Eisai and Digital Garage, Inc. Jointly Launch "Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)" Nov 04, 2021 10:06 HKT/SGT Read More
Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study Nov 04, 2021 09:39 HKT/SGT Read More
Cryoviva Singapore Gets AABB Accreditation for Somatic Cells' Processing, Storage, and Distribution Nov 02, 2021 08:30 HKT/SGT Read More
エーザイとPRISM BioLab共同創製のCBP/β-catenin 阻害剤 E7386 について、臨床における POC(Proof of Concept:創薬概念の検証)を達成 Nov 01, 2021 10:00 JST Read More
The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept) Nov 01, 2021 08:41 HKT/SGT Read More
휴머니젠, 유럽핵의학회에서 임상1상 연구 결과 발표에 이어 고형 종양 관련 이파보투주맙 임상 1b상 연구를 준비하고 있다고 발표함 Oct 31, 2021 14:00 HKT/SGT Read More
휴머니젠, 체스트 연례회의(CHEST Annual Meeting)에서 렌질루맙 치료를 통해 최적의 효과를 볼 수 있을 것으로 보이는 환자군을 파악하기 위한 바이오마커로써의 C-반응성 단백질에 관한 최신 발표 Oct 25, 2021 11:00 HKT/SGT Read More
Universities and DENSO Develop Biosensor to Detect SARS-CoV-2 and Accelerate Development for Practical Application Oct 21, 2021 15:41 HKT/SGT Read More